Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva presented new real-world data at Psych Congress showing UZEDY patients with schizophrenia stayed on treatment longer than those on other long-acting injectables, including a 40% lower all-cause emergency department visit rate versus once-monthly paliperidone palmitate (22.0% vs. 27.8%). Mean monthly direct healthcare costs were $4,688.10 for UZEDY versus $5,724.80 for paliperidone palmitate, an adjusted savings of $1,036.70 per patient per month; against risperidone microspheres, UZEDY patients had 3.6x higher odds of adherence.
Key figures
- Drug Name
- UZEDY (risperidone)
- Study type
- real-world observational analyses and retrospective chart review presented at Psych Congress
- Bd1 matched cohort
- 358
- Ed visit rate uzedy vs pp1m
- 22.0% vs. 27.8%
- Schizophrenia matched cohort
- 1166
- All cause ed visit rate reduction
- 40%
- Hospitalization rate uzedy vs pp1m
- 11.1% vs. 14.8%
- Bd1 treatment failure uzedy vs oral
- 47% vs. 63%
- Adherence odds ratio vs risperidone microspheres
- 3.6
- Discontinuation odds ratio vs risperidone microspheres
- 0.2
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.